Which antibody and ELISA kit targets are researchers interested in for cancer research?
5
Min Read
In this blog:
- We focus on the RUO ELISA kit market and the RUO Antibody market
- Which targets are widely cited in the cancer research literature?
- Which institutions and countries are highly active in the oncology space?
CiteAb collects data on reagent use from the scientific literature, powering a search engine to help scientists find products and market data & citation provision services for suppliers, pharma and financial companies.
With the AACR meeting approaching, today we are sharing key insights into Cancer Research antibodies and ELISA kits to help you stay ahead of trends in this space.
We answer three key questions:
- Which cancer research antibody and ELISA Kit targets are researchers citing widely?
- Where is demand growing the fastest – in which institutions?
- And in which countries?
Plus, we’re sharing a free data download covering the top ten antibody and ELISA kit cancer research targets at the bottom of this blog.
Market Demand: RUO Antibody and ELISA kit Use in Cancer Research
RUO antibodies and ELISA kits are vital tools helping to drive progress in oncology. Demonstrating this, Cancer Research is consistently a research area with one of the highest quantities of citations for RUO antibody and ELISA kits.
Between 2022-2024 in the published literature, we recorded:
- 200 antibody suppliers and 60k antibody products
- Nearly 100 ELISA suppliers and 3k ELISA kits
- Together, ELISA kits and antibodies saw over 259k citations (instances of these products supporting research).
Given such a significant research need, which targets are scientists interested in?
Popular Targets: Which Cancer Markers Are Researchers Focusing On?
Oncology ELISA Kit Target Trends:
Looking at our ELISA kit data, we found that Interferon gamma claimed the top spot as the highest cited oncology target. This is a widely studied cytokine across many research areas such as immunology and infectious disease research.
Interferon gamma has key functions in the immune system, and is being explored as a potential target for cancer immunotherapy with complex roles in tumor growth (both positive and negative). It claimed a 11.37% market share in 2024.
Another target seeing strong and steady growth, demonstrating sustained interest from researchers translating into results, is Tumor Necrosis Factor (TNF). TNF claimed a share of 7.66% in 2024, the second most cited target.
Taking the third most cited spot was another popular cytokine: Interleukin-6. This target has seen the opposite trend of Interferon gamma, with a declining citation share from 8.43% in 2015 to around 5% in 2024.
Many of the top ELISA kit targets were cytokines; several cytokines are currently in clinical trials. [1]
Further targets in the top 20 that have been growing in citation share more recently include Interleukin-10 and Transforming growth factor beta-1 proprotein. Does your ELISA kit portfolio cover these targets?
Citation data can reveal trends for thousands of ELISA kit targets. Top suppliers use this data to compare portfolios against the growing targets and spot gaps or campaign opportunities.
Oncology antibody target trends:
Turning our analysis to cancer research antibodies, we found the top three cited targets to be:
- Glyceraldehyde-3-phosphate dehydrogenase
- RAC-alpha serine/threonine- protein kinase
- Actin, cytoplasmic 1
More specific targets that were in the top 20 cited list included Ki-67 and Myc proto-oncogene. You can download a list of the top 10 to expand your analysis at the bottom of this blog.
We also found a number of targets seeing growing research interest. These included: T-cell surface glycoprotein CD8 alpha chain and Programmed cell death 1 ligand 1.
T-cell surface glycoprotein CD8 alpha chain is a marker for CD8+ T cells, studies of which can feed into T-cell based therapies. Are you seeing increasing interest for this target in your company?
Reach out to the team to discuss how our market data can help power even more granular questions, such as application or company share.
Regional and Institutional Insights: Where is Demand Growing the Fastest?
Now that we’ve covered antibody and ELISA kit targets, we drill down into which countries and institutions are driving this demand.
For the cancer research ELISA kit space, we saw that Chinese Universities outputted the most citations, with 9 of the top 10 institutions by citation count based here. Sun Yat-sen University led.
A few US institutions also appeared in the top 20; notably the University of Texas, claiming the third largest citation count overall.
This reflects broader country trends, with China seeing a 32% citation share in 2023. Joining them in the top three were the US and Germany, both seeing a downward trajectory.
Countries you may want to watch include Italy and South Korea, both seeing growth over more recent years.
We saw very similar trends in the RUO cancer research antibody space. Sun Yat Sen university led here.
We commented on Asia overtaking the US on our blog several years ago – it seems this trend has continued, and China now claims around 44% of cancer research antibody citations.
Active US institutions in the cancer research space included the Dana Faber Institute and the National Cancer Institute, Bethesda – both of which saw a rising citation share in 2023.
In addition, Taiwan and Hong Kong also saw a couple of institutions in the top 100 – with Hong Kong seeing a general citation increase. Are you seeing an uptick in demand there?
What data was used for this analysis?
For this analysis we drew on hundreds of thousands of citations collected using our proprietary text mining technology from open and closed access literature, combined with scientist reviewing for maximum accuracy.
Our antibody database covers nearly 8 million products, and our Kits & Assays Database over 1m products.
Key Takeaways for Reagent Suppliers + Data Download
Keeping up to date with the latest insight on reagent use is essential for companies looking to provide the best products for researchers, and drive more successful campaigns.
- By understanding popular targets, you can meet evolving researcher needs.
- By understanding geographic trends, you can ensure your products are reaching the right people.
To gain more insight, you can download data below on the top 10 cancer research ELISA kit and Antibody targets.
Finally, for further information, please reach out to the team here!
Sign up for data
Something seems to have gone wrong while loading the form.
Drop us a message and we can send you the data directly.
References
